Sponsor content
68 result(s) found, displaying 11 to 20
-
Australian public assessment report (AusPar)Abrysvo is a vaccine that provides active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).
-
Australian public assessment report (AusPar)Nurtec ODT (rimegepant) has been approved for the treatment of acute migraine and the prophylactic treatment of episodic migraine in adults
-
Australian public assessment report (AusPar)Comirnaty Omicron XBB.1.5 (raxtozinameran) COVID-19 vaccine has been approved for the prevention of COVID-19 in individuals 6 months to 12 years old.
-
Australian public assessment report (AusPar)Comirnaty Original/Omicron BA.4-5 (tozinameran/famtozinameran) is provisionally approved to prevent COVID-19 in individuals 5 years of age and older.
-
Australian public assessment report (AusPar)Comirnaty (tozinameran), a vaccine, has been approved for the prevention of coronavirus disease 2019 (COVID-19) in individuals 12 years of age and older.
-
Australian public assessment report (AusPar)AusPAR for full registration for COMIRNATY (tozinameran) for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
-
Australian public assessment report (AusPar)AusPAR for Prevenar 20 (pneumococcal polysaccharide conjugate vaccine) for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.
-
Australian public assessment report (AusPar)AusPAR for Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine (tozinameran and famtozinam) for prevention of COVID-19.
-
Australian public assessment report (AusPar)AusPAR for Ngenla (somatrogon) for treatment of paediatric patients with growth disturbance due to insufficient growth hormone.
-
Australian public assessment report (AusPar)AusPAR for Comirnaty Original/Omicron BA.1 COVID-19 vaccine (tozinameran and riltozinameran) for prevention of COVID-19.